Bellerophon Therapeutics (NASDAQ:BLPH) Now Covered by StockNews.com

Analysts at StockNews.com began coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH) in a report issued on Sunday. The firm set a “hold” rating on the biotechnology company’s stock.

Bellerophon Therapeutics Stock Performance

Shares of Bellerophon Therapeutics stock opened at $0.04 on Friday. The firm has a market cap of $440,388.00, a PE ratio of -0.04 and a beta of 0.70. The stock has a 50 day moving average of $0.04 and a 200 day moving average of $0.05. Bellerophon Therapeutics has a 12 month low of $0.03 and a 12 month high of $0.42.

Bellerophon Therapeutics Company Profile

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.